Vertex Pharmaceuticals (VRTX) Revenue — Quarter Ended Mar 31, 2024
Revenue increased compared to the immediately preceding quarter. Revenue also rose versus the same quarter one year earlier.
Key takeaway
Quarter ended Mar 31, 2024 · FY2024 Q1
Revenue increased compared to the immediately preceding quarter. Revenue also rose versus the same quarter one year earlier.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$2.7B
Revenue reported for this quarter.
Quarter-over-quarter
+6.9%
Change from the immediately preceding quarter.
Year-over-year
+13.3%
Change from the comparable year-ago quarter.
Trailing four quarters
$10.2B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2023 | $2.5B | +13.5% |
| Sep 30, 2023 | $2.5B | +6.4% |
| Dec 31, 2023 | $2.5B | +9.3% |
| Mar 31, 2024 | $2.7B | +13.3% |
Revenue performance
The reported revenue for the quarter was higher than both the prior quarter and the year-ago period. The sequential and year-over-year comparisons both show positive movement.
Quarterly comparison
Compared to the immediately preceding quarter, revenue improved. Against the same quarter last year, revenue also increased.
What to watch
Monitoring the sustainability of revenue growth will be important in upcoming quarters.